PDCD1LG2 and Hodgkins lymphoma: Cytogenetic studies have shown an amplification in copy number of the programmed cell death ligand (PDL1 and PDL2) gene loci in the majority of HL cases, leading to the up‐regulation of PDL1 and PDL2 surface expression.18 Nivolumab is an antiprogrammed cell death (anti‐PD1) IgG4 monoclonal antibody, currently licenced for relapsed HL, which targets the PD1 T‐cell surface receptor interaction.